Skip to main content
SpringerLink
Log in

Renal Safety of Intravenous Ibandronic Acid in Breast Cancer Patients with Metastatic Bone Disease

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Introduction: Renal adverse events are a troublesome complication of bisphosphonate therapy. This study investigated the effect of intravenous ibandronic acid (ibandronate) treatment on renal function in breast cancer patients with metastatic bone disease.

Methods: 74 patients were randomised to double-blind (but not dose-blind) treatment with bolus injections of ibandronic acid 2mg (n = 23), 1-hour infusions of ibandronic acid 6mg (n = 28), or placebo injections or infusions (n = 23). According to randomisation, patients received either three injections or three infusions over the 3-month period, one at the start and two subsequent doses at 4-weekly intervals. Measurements of urinary excretion of total protein, albumin, α1-microglobulin, N-acetyl-β-D-glucosaminidase, haematuria and serum creatinine were performed before, during and after treatment.

Results: Treatment with ibandronic acid was not associated with impairment of renal function; the renal safety profiles of ibandronic acid 2 and 6mg were similar to that of placebo. Assessments of proteinuria, haematuria, enzymuria and serum creatinine indicated that there were no statistically significant changes between pre- and post-treatment levels in patients receiving ibandronic acid 2 or 6mg or between patients receiving ibandronic acid or placebo. Urine parameters varied during treatment in the same range with approximately similar frequency in the ibandronic acid and placebo groups.

Conclusions: Short-term administration of intravenous ibandronic acid did not impair renal function in breast cancer patients with metastatic bone disease. Because tolerability profiles vary between bisphosphonates, the lack of renal toxicity with ibandronic acid makes the drug an attractive treatment option for metastatic bone disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

Notes

  1. 1The use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Fleish H. Bisphosphonates in bone disease: from the laboratory to the patient. New York: The Parthenon Publishing Group Ltd, 1995: 176

    Google Scholar 

  2. Kanis JA, O’Rourke N, McCloskey EV. Consequences of neoplasia induced bone resorption and the use of clodronate. Int J Oncol 1994; 5: 713–31

    PubMed  CAS  Google Scholar 

  3. Scharia SH, Minne HW, Sattar P, et al. Therapie der Tumorhypercalciämie mit Clodronat: Einfluss auf Parathormon und Calcitriol. Dtsch Med Wochenschr 1987; 112: 1121–5

    Article  Google Scholar 

  4. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016–21

    Article  PubMed  Google Scholar 

  5. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320–2

    Article  PubMed  CAS  Google Scholar 

  6. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389–406

    Article  PubMed  CAS  Google Scholar 

  7. Yates AJ, Percival CJ, Gray RE, et al. Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1985; I: 1474–7

    Article  Google Scholar 

  8. Bounameaux HM, Schifferli J, Montani JP, et al. Renal failure associated with intravenous diphosphonates [letter]. Lancet 1983; I: 471

    Article  Google Scholar 

  9. Francis MD, Slough CL. Acute intravenous infusion of disodium dihydrogen (I-hydroxyethylidene) diphosphonate: mechanism of toxicity. J Pharm Sci 1984; 73: 1097–100

    Article  PubMed  CAS  Google Scholar 

  10. Kanis JA, Preston CJ, Yates AJ, et al. Effects of intravenous diphosphonates on renal function [letter]. Lancet 1983; I: 1328

    Article  Google Scholar 

  11. Markowitz GS, Appel GB, Fine PL. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164–72

    PubMed  CAS  Google Scholar 

  12. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377–87

    PubMed  CAS  Google Scholar 

  13. Hofmann W, Guder WG. A diagnostic programme for quantitative analysis of proteinuria. J Clin Chem Clin Biochem 1989; 27: 589–600

    PubMed  CAS  Google Scholar 

  14. Hofmann W, Regenbogen C, Edel H, et al. Diagnostic strategies in urinalysis. Kidney Int Suppl 1994; 46: S111–114

    Google Scholar 

  15. Scherberich JE. Urinary proteins of tubular origin: basic immunochemical and clinical aspects. Am J Nephrol 1990; 10: 43–51

    Article  PubMed  Google Scholar 

  16. Price RG. Urinary enzymes, nephrotoxicity and renal disease. Toxicology 1982; 23: 99–134

    Article  PubMed  CAS  Google Scholar 

  17. Recio E, Villamil E, Recio C, et al. Utility of filtration markers to monitor the quality of glomerular function. Clin Nephrol 1992; 38: S8–13

    PubMed  Google Scholar 

  18. Guder WG, Hofmann W. Markers for the diagnosis and monitoring of renal tubular lesions. Clin Nephrol 1992; 38: S3–7

    PubMed  Google Scholar 

  19. Vanderlinde RL. Urinary enzyme measurements in the diagnosis of renal disorders. Ann Clin Lab Sci 1981; 11: 189–201

    PubMed  CAS  Google Scholar 

  20. Mühlbauer RC, Bauss F, Schenk R, et al. Ibandronate, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 9: 1003–11

    Google Scholar 

  21. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996; 14: 268–76

    PubMed  CAS  Google Scholar 

  22. Ralston SH, Thiébaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 1997; 75: 295–300

    Article  PubMed  CAS  Google Scholar 

  23. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003 Sep; 14: 1399–405

    Article  PubMed  Google Scholar 

  24. Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer. In press

  25. Pecherstorfer M, Ludwig H, Schlosser K, et al. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996; 11: 587–93

    Article  PubMed  CAS  Google Scholar 

  26. Rossi RM, Kist C, Wurster U, et al. Estimation of ifosfamide/ cisplatinum-induced renal toxicity by urinary protein analysis. Pediatr Nephrol 1994; 8: 151–6

    Article  PubMed  CAS  Google Scholar 

  27. Verplanke AJ, Herber RF, de Wit R, et al. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity. Nephron 1994; 66: 267–72

    Article  PubMed  CAS  Google Scholar 

  28. Viberti GC, Mogensen CE, Keen H, et al. Urinary excretion of albumin in normal man: the effect of water loading. Scand J Clin Lab Invest 1982; 42: 147–57

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

We thank Drs EV Stogova and VM Abaev for their technical assistance with the renal parameters studies and Dr AA Meshcheryakov for his assistance with the interpretation of clinical information.

Author information

Authors and Affiliations

  1. Laboratory of Clinical Biochemistry, NN Blokhin Cancer Research Centre, 24 Kashirskoe sh., 115478, Moscow, Russia

    Nina V. Lyubimova & Nikolay E. Kushlinsky

  2. Department of Chemotherapy and Combined Methods of Treatment, NN Blokhin Cancer Research Centre, Moscow, Russia

    Michail R. Lichinitser

  3. Department of Clinical Research Roche, GmbH, Mannheim, Germany

    Karl Schlosser

Authors
  1. Nina V. Lyubimova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolay E. Kushlinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michail R. Lichinitser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karl Schlosser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyubimova, N.V., Kushlinsky, N.E., Lichinitser, M.R. et al. Renal Safety of Intravenous Ibandronic Acid in Breast Cancer Patients with Metastatic Bone Disease. Clin. Drug Investig. 23, 707–716 (2003). https://doi.org/10.2165/00044011-200323110-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200323110-00003

Keywords

Search

Navigation